CN106860427A - A kind of cerium oxide/iron oxide/nanometer composite and its preparation method and application - Google Patents
A kind of cerium oxide/iron oxide/nanometer composite and its preparation method and application Download PDFInfo
- Publication number
- CN106860427A CN106860427A CN201710039529.8A CN201710039529A CN106860427A CN 106860427 A CN106860427 A CN 106860427A CN 201710039529 A CN201710039529 A CN 201710039529A CN 106860427 A CN106860427 A CN 106860427A
- Authority
- CN
- China
- Prior art keywords
- cerium oxide
- oxide
- nanometer
- nanometer composite
- iron oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a kind of cerium oxide/iron oxide/nanometer composite, the ferric oxide nano crystalline substance of the cerium oxide nanocrystal that part is changed and part conversion is modified in the surface of amido modified nanometer particle respectively.The invention further relates to the preparation method and application of cerium oxide/iron oxide/nanometer composite.The composite can carry AD medicines, the ROS in class AD cells can be removed again, and, for the diagnosis of AD, can realize the diagnosis and treatment integration of AD as NMR contrast agent.
Description
Technical field
The invention belongs to the preparation field of composite, and in particular to a kind of cerium oxide/iron oxide/nanometer is combined
Material and its preparation method and application.
Background technology
Alzheimer disease (Alzheimer ' s disease, AD) also known as senile dementia, be cerebral hemisphere language,
A kind of nerve degenerative diseases that the intelligence such as memory and reasoning is produced in compromise state, are incidence of disease highests in the aged
One of disease, serious harm human health.The survey showed that for world pop disease of 2005, and the current whole world is
There are 24,300,000 alzheimer patients, annual new cases 4,600,000 (just have 1 new patient for every 7 seconds).And this quantity is every
1 times will be increased within 20 years, to the year two thousand forty, sum is likely to be breached 81,100,000, and most of patient concentrates on developing country.According to pre-
Survey, the alzheimer disease patient populations of China will increase by 3 times from 2001 to the year two thousand forty, when the time comes Chinese stages alzheimer's disease
Patient is up to 15,000,000, and this will turn into a serious social concern.
The first alzheimer patient was found from 1906 so far, more than 100 years has been have passed through.In over one hundred year, although people
Class has the understanding for deepening continuously to the pathogenic process and mechanism of alzheimer disease, but the mankind lack to alzheimer disease
Effective treatment method is still a undisputable fact.It is related to factors on its pathogenesis at present, there are various hypothesis, this
A little theories partly explain the pathogenesis of AD.For the different target spots of AD pathogenesis, the more treatment of kind is occurred in that
AD medicines.1. anti-amyloid beta protein：With suppress A β be produced as the β of target-, γ-cutting enzyme inhibitor；It is to suppress A beta peptide aggregations
The resistant to aggregation medicine (including metal-chelator) of target；And to remove A β as the proteinase activity regulating medicine of target and be immunized
Treatment.2. anti-Protein tau phosphorylation：It is transformed into oligomer and filametntary Tau agglutination inhibitors to suppress Tau albumen；To press down
The phosphokinase inhibitor of Tau protein phosphorylations processed.Additionally, research finds that active oxygen radical (ROS) also has to the formation of AD
Certain facilitation, therefore the medicine of anti-oxidation stress is also one of therapy target of AD.
In addition to without effective treatment method, up to the present, not yet find has specific to the clinical diagnosis of AD
Mark.It has long been believed that AD's makes a definite diagnosis pathological diagnosis to be leaned on, and think except pathological diagnosis, be correct diagnosis is made before death
Impossible, clinical misdiagnosis can reach 27~57%.If the therapeutic alliance of Mutiple Targets can be given while Precise Diagnosis AD
Above-mentioned problem must be solved, therefore, the preparation for building diagnosis and treatment integration is particularly important.
With the fast development of nanometer technology for AD diagnosis and treatment integrations bring new hope.It is steady by optimizing material construction
Fixed, efficient and safe nano-carrier, the AD for combining new AD medicines and high accuracy using nano-carrier is diagnosed and visited
Pin, integrating the functions such as drug targeting transport, vivo tracking, drug therapy and Prognosis scoveillance will in the multifunctional nano system of one
It is following research tendency.
The content of the invention
The purpose of the present invention is to solve the shortcomings of the prior art, there is provided a kind of cerium oxide/iron oxide/nanometer is multiple
Condensation material and its preparation method and application.
Technical scheme provided by the present invention is：
A kind of cerium oxide/iron oxide/nanometer composite, the cerium oxide nanocrystal that part is changed and part turn
The ferric oxide nano crystalline substance for changing is modified in the surface of amido modified nanometer particle respectively.
In above-mentioned technical proposal, the above-mentioned cerium oxide/iron oxide/nanometer composite for being provided can carry AD
Medicine, removes the ROS in class AD nerve cells, and the function with NMR contrast agent, realizes the diagnosis and treatment of AD
Integration.
First, nanometer particle has great pore volume, can carry the medicine of AD treatments, and in lesion
Position sustained release, reaches therapeutic action；Secondly, cerium oxide nanocrystal can in balanced class AD nerve cells elevated active oxygen from
By base, and then reduce the oxidativestress damage that active oxygen radical is caused；Ferric oxide nano is brilliant, and there is good nuclear magnetic resonance to make
Shadow effect, strengthens diseased region nuclear magnetic signal, for the diagnosis of AD.
Preferably, the part conversion refers to carry out part conversion using 2- bromo acids.In order to cerium oxide is received
Meter Jing and ferric oxide nano crystalline substance are connected to nanometer particle surface in the form of the covalent bond of stabilization, first with 2- bromo isobutyls
Acid part conversion is carried out to cerium oxide nanocrystal, then nanometer particle surface is carried out it is amido modified, be conducive to both it
Between it is compound, finally cause to realize after three kinds of Material claddings multifunctional integrated.
Preferably, the particle diameter of cerium oxide nanocrystal that the part is changed is 1~10nm；The oxidation of the part conversion
The nanocrystalline particle diameter of iron is 1~10nm；The particle diameter of the amido modified nanometer particle is 5~500nm.Above-mentioned grain
Footpath scope, be easy to cerium oxide nanocrystal, ferric oxide nano it is brilliant it is uniform must modify in the surface of nanometer particle, obtain pattern
With the composite of excellent performance.
The present invention provides a kind of preparation method of cerium oxide/iron oxide/nanometer composite described above, including
Following steps：
1) cerous acetate and oleyl amine are added in dimethylbenzene and are reacted, obtain cerium oxide nanocrystal；Using 2- bromo acids
Part conversion is carried out, the cerium oxide nanocrystal of part conversion is obtained；
2) iron oleate, oleic acid, oleyl alcohol are added in octadecylene and are reacted, obtain ferric oxide nano brilliant；Using 2- bromo isobutyls
Acid carries out part conversion, and the ferric oxide nano for obtaining part conversion is brilliant；
3) hexadecyltrimethylammonium chloride and triethanolamine are dissolved in water, 0.5~5h is reacted at 90~100 DEG C, after
It is continuous to add tetraethyl orthosilicate and 3- aminopropyl triethoxysilanes to react 0.5~5h, obtain amido modified nanometer grain
Son；
4) the brilliant and amido modified mesoporous silicon of the ferric oxide nano of the cerium oxide nanocrystal of part conversion, part conversion is received
Rice corpuscles is added in N-N dimethylformamides, and 3~15h is reacted at 5~60 DEG C, obtains cerium oxide/iron oxide/mesoporous silicon
Nano composite material.
Using above-mentioned preparation method, cerium oxide/iron oxide/nanometer composite, the composite wood can be prepared
Material can carry AD medicines, and the ROS in class AD nerve cells can be removed again, and can be used as Magnetic resonance imaging radiography
Agent, for the diagnosis of AD.Therefore, by the compound of multiple material, the diagnosis and treatment integration preparation for AD is constructed.
Preferably, the step 1) in the mass ratio of cerous acetate and oleyl amine be 1:7~9.
Preferably, the step 1) in cerous acetate hydrate and oleyl amine are added in dimethylbenzene, at 85~95 DEG C
3~6h of reaction, cooling, precipitation, washing, obtains cerium oxide nanocrystal.
Preferably, the step 1) in part conversion refer to：The cerium oxide nanocrystal that to obtain, 2- bromo acids and
Citric acid is added sequentially to stir 2~30h in the mixed solvent of chloroform and N-N dimethylformamides.Part conversion is to incite somebody to action
Cerium oxide nanocrystal is connected to nanometer particle surface in the form of the covalent bond of stabilization.Further preferably, the step 1)
Middle 2- bromo acids are 20~60 with the mass ratio of cerium oxide nanocrystal：1.
Preferably, the step 2) in iron oleate, oleic acid, oleyl alcohol and octadecylene mass ratio be 1：0.15~0.6：
0.5~2：2.5~10.
Preferably, the step 2) in iron oleate, oleic acid, oleyl alcohol are added in octadecylene, it is anti-at 200~300 DEG C
30~60min is answered, cooling, precipitation, washing obtain ferric oxide nano brilliant.
Preferably, the step 2) in part conversion refer to：The ferric oxide nano that to obtain is brilliant, 2- bromo acids and
Citric acid is added sequentially to stir 2~30h in the mixed solvent of chloroform and N-N dimethylformamides.Part conversion is to incite somebody to action
Ferric oxide nano is brilliant to be connected to nanometer particle surface in the form of the covalent bond of stabilization.Further preferably, the step 1)
Middle 2- bromo acids are 20~60 with the brilliant mass ratio of ferric oxide nano：1.
Preferably, the step 3) in hexadecyltrimethylammonium chloride, triethanolamine, tetraethyl orthosilicate and 3- ammonia third
The rate of charge of ethyl triethoxy silicane alkane is：1.5~2.5g：0.03~0.05g：1.4~1.6ml：0.14~0.16ml.
Preferably, the step 4) in the cerium oxide nanocrystal of part conversion, part conversion ferric oxide nano it is brilliant and
The mass ratio of amido modified nanometer particle is 1~5：1~5：1~15.By regulating and controlling the mass ratio between three, control
The cerium oxide nanocrystal of part conversion processed and the brilliant content of the ferric oxide nano of part conversion so that the cerium oxide of part conversion is received
Meter Jing and the ferric oxide nano crystalline substance of part conversion are easy to modify in amido modified nanometer particle surface, are easy to pattern
Regulation and control.
The present invention also provides a kind of cerium oxide/iron oxide/nanometer composite described above anti-for preparing
Application in alzheimer disease drug.Cerium oxide/iron oxide/nanometer the composite can carry AD curatives
Thing.
Preferably, described AD medicines be β-, γ-cutting enzyme inhibitor, proteinase activity regulating medicine, be immunized
One or more in medicine, Tau agglutination inhibitors, Tau Hyperphosphorylationof inhibitor.
Preferably, the medicine resisting Alzheimer disease is the medicine with Tau albumen as target spot.Cerium oxide/iron oxide/
After nanometer composite carries the medicine with Tau albumen as target spot, being capable of scavenging capacity oxygen radical, reduction tau eggs
White phosphorus is acidified, and suppresses the effect of neuronal death.
Compared with the existing technology, beneficial effects of the present invention are embodied in：
(1) cerium oxide/iron oxide/nanometer composite in the present invention can carry AD medicines, and energy
The ROS in class AD cells is removed, and can be as NMR contrast agent, for the diagnosis of AD.
(2) reaction system of preparation method involved in the present invention is gentle, and condition is controllable, and prepared material is respectively provided with good
Good biocompatibility, with good clinical conversion possibility.
Brief description of the drawings
Fig. 1 is the cerium oxide nanocrystal of the part conversion in embodiment 1, the ferric oxide nano crystalline substance of part conversion and oxidation
The XRD of cerium/iron oxide/nanometer composite；
Fig. 2 is the TEM of the ferric oxide nano crystalline substance b of the cerium oxide nanocrystal a and part conversion of the part conversion in embodiment 1
Photo；
Fig. 3 is the TEM photos of the amido modified nanometer particle in embodiment 1；
Fig. 4 is the TEM photos of the cerium oxide/iron oxide/nanometer composite in embodiment 1；
Fig. 5 be in application examples different cerium oxide/iron oxide/mesoporous silicon/methylenum careuleum nano composite material containing concentration to SH-
The CCK-8 cytoactive quantitative analysis results figures of SY5Y cell biological compatibilities；
Fig. 6 suppresses to contain the different cerium oxide/iron oxide/mesoporous silicon of concentration/methylenum careuleum nano composite material in application examples
The CCK-8 cytoactive quantitative analysis results figures of the SH-SY5Y cell deaths of OA inductions.
Specific embodiment
With reference to specific embodiment and Figure of description, the invention will be further described.
Embodiment 1
(1) synthesis of cerium oxide nanocrystal and part are changed：0.4g cerous acetates hydrate and 3.2g oleyl amines are added to
In 15ml dimethylbenzene, it is stirred at room temperature 4 hours, 90 degrees Celsius is risen to the programming rate of 2 centigrade per minutes；By 1ml deionizations
To in inert gas shielding reaction system, aging three hours, acetone precipitation, centrifugation obtained cerium oxide nanocrystal to water injection.
Cerium oxide nanocrystal 15mg, 0.5g 2- bromo acids and 0.05g citric acids that synthesis is obtained are added sequentially to
Stirring is obtained final product for 24 hours in the mixed solvent of 7.5ml chloroforms and 7.5ml N,N-dimethylformamides.
The cerium oxide nanocrystal of the part conversion to obtaining carries out X-ray diffraction, as shown in Figure 1；And part is turned
The cerium oxide nanocrystal for changing carries out morphology characterization with transmission electron microscope, as depicted in figure 2.
(2) the brilliant synthesis of ferric oxide nano and part conversion：1.8g iron oleates, 0.6g oleic acid, 1.6g oleyl alcohol are added to
In 10g octadecylenes.It is stirred at room temperature, 280 degrees Celsius is risen to the programming rate of 10 centigrade per minutes.Maintain temperature 30 minutes,
Room temperature is cooled to, with acetone precipitation, it is brilliant that centrifugation obtains ferric oxide nano.
Ferric oxide nano crystalline substance 15mg, 0.5g 2- bromo acids and 0.05g citric acids that synthesis is obtained are added sequentially to
Stirring is obtained final product for 24 hours in the mixed solvent of 7.5ml chloroforms and 7.5ml N,N-dimethylformamides.
The cerium oxide nanocrystal of the part conversion to obtaining carries out X-ray diffraction, as shown in Figure 1；And part is turned
The cerium oxide nanocrystal for changing carries out morphology characterization with transmission electron microscope, as shown in accompanying drawing 2b.
(3) synthesis of amido modified mesoporous silicon dioxide nano particle：By 2g hexadecyltrimethylammonium chlorides and
0.02g triethanolamines are added in 20ml deionized waters, and stirring is warming up to 95 degrees Celsius, add tetraethyl orthosilicate 1.5ml and 150
μ L 3- aminopropyl triethoxysilane stirring reactions 1h.Template is washed away by centrifugation and 1wt% sodium chloride methanol solutions
Obtain amido modified nanometer particle.
Amido modified nanometer particle to preparing carries out transmission electron microscope morphology characterization, such as Fig. 3
It is shown.
(4) synthesis of cerium oxide/iron oxide/nanometer composite：It is 3mg/ by the concentration that 2.5ml parts are changed
The DMF solution of ml cerium oxide nanocrystals, the concentration that 5ml parts are changed is 3mg/ml cerium oxide nanocrystals
N,N-dimethylformamide solution and 10ml 5mg/ml it is amido modified mesoporous silicon dioxide nano particle N, N- diformazans
Base formamide solution can obtain cerium oxide/iron oxide/nanometer composite in 12 hours in 30 degrees Celsius of reactions.
Tem study, acquired results are carried out to obtaining cerium oxide/iron oxide/nanometer composite
As shown in Figure 4, a diameter of 50~60nm of the nano composite material of cerium oxide/iron oxide/mesoporous silicon.
Embodiment 2
(1) synthesis of cerium oxide nanocrystal and part are changed：0.4g cerous acetates hydrate and 3.6g oleyl amines are added to
In 15ml dimethylbenzene, it is stirred at room temperature 6 hours, 95 degrees Celsius is risen to the programming rate of 2 centigrade per minutes；By 1ml deionizations
To in inert gas shielding reaction system, aging three hours, acetone precipitation, centrifugation obtained cerium oxide nanocrystal to water injection.
Cerium oxide nanocrystal 10mg, 0.5g 2- bromo acids and 0.05g citric acids that synthesis is obtained are added sequentially to
Stirring is obtained final product for 12 hours in the mixed solvent of 7.5ml chloroforms and 7.5ml N,N-dimethylformamides.
(2) the brilliant synthesis of ferric oxide nano and part conversion：2g iron oleates, 1g oleic acid, 2g oleyl alcohol are added to 10g 18
In alkene.It is stirred at room temperature, 300 degrees Celsius is risen to the programming rate of 10 centigrade per minutes.Maintain temperature 40 minutes, be cooled to room
Temperature, with acetone precipitation, it is brilliant that centrifugation obtains ferric oxide nano.
Ferric oxide nano crystalline substance 10mg, 0.5g 2- bromo acids and 0.05g citric acids that synthesis is obtained are added sequentially to
Stirring is obtained final product for 12 hours in the mixed solvent of 7.5ml chloroforms and 7.5ml N,N-dimethylformamides.
(3) synthesis of amido modified nanometer particle：By 2.4g hexadecyltrimethylammonium chlorides and 0.05g tri-
Monoethanolamine is added in 20ml deionized waters, and stirring is warming up to 95 degrees Celsius, adds tetraethyl orthosilicate 1.4ml and 160 μ L 3- ammonia
Propyl-triethoxysilicane stirring reaction 0.5 hour.Obtained by washing away template by centrifugation and 1wt% sodium chloride methanol solutions
To amido modified nanometer particle.
(4) synthesis of cerium oxide/iron oxide/nanometer composite：It is 3mg/ml by the concentration that 3ml parts are changed
The DMF solution of cerium oxide nanocrystal, the concentration that 6ml parts are changed is 3mg/ml cerium oxide nanocrystals
The N of the 5mg/ml of N,N-dimethylformamide solution and 12ml amido modified mesoporous silicon dioxide nano particle, N- dimethyl
Formamide solution can obtain cerium oxide/iron oxide/nanometer composite in 8 hours in 40 degrees Celsius of reactions.
Embodiment 3
(1) synthesis of cerium oxide nanocrystal and part are changed：0.4g cerous acetates hydrate and 2.8g oleyl amines are added to
In 15ml dimethylbenzene, it is stirred at room temperature 3 hours, 85 degrees Celsius is risen to the programming rate of 2 centigrade per minutes；By 1ml deionizations
To in inert gas shielding reaction system, aging three hours, acetone precipitation, centrifugation obtained cerium oxide nanocrystal to water injection.
Cerium oxide nanocrystal 20mg, 0.5g 2- bromo acids and 0.05g citric acids that synthesis is obtained are added sequentially to
Stirring is obtained final product for 4 hours in the mixed solvent of 7.5ml chloroforms and 7.5ml N,N-dimethylformamides.
(2) the brilliant synthesis of ferric oxide nano and part conversion：2g iron oleates, 1.2g oleic acid, 2.5g oleyl alcohol are added to 10g
In octadecylene.It is stirred at room temperature, 250 degrees Celsius is risen to the programming rate of 10 centigrade per minutes.Maintain temperature 30 minutes, cooling
To room temperature, with acetone precipitation, it is brilliant that centrifugation obtains ferric oxide nano.
Ferric oxide nano crystalline substance 20mg, 0.5g 2- bromo acids and 0.05g citric acids that synthesis is obtained are added sequentially to
Stirring is obtained final product for 4 hours in the mixed solvent of 7.5ml chloroforms and 7.5ml N,N-dimethylformamides.
(3) synthesis of amido modified nanometer particle：By 2g hexadecyltrimethylammonium chlorides and the second of 0.04g tri-
Hydramine is added in 20ml deionized waters, and stirring is warming up to 95 degrees Celsius, adds tetraethyl orthosilicate 1.4ml and 160 μ L 3- ammonia third
Ethyl triethoxy silicane alkane stirring reaction 0.5 hour.Template is washed away by centrifugation and 1wt% sodium chloride methanol solutions to can obtain
Amido modified nanometer particle.
(4) synthesis of cerium oxide/iron oxide/nanometer composite：It is 3mg/ml by the concentration that 4ml parts are changed
The DMF solution of cerium oxide nanocrystal, the concentration that 5ml parts are changed is 3mg/ml cerium oxide nanocrystals
The N of the 5mg/ml of N,N-dimethylformamide solution and 10ml amido modified mesoporous silicon dioxide nano particle, N- dimethyl
Formamide solution can obtain cerium oxide/iron oxide/nanometer composite in 4 hours in 25 degrees Celsius of reactions.
Application examples：Cerium oxide/iron oxide/mesoporous silicon receives/and methylenum careuleum nano composite material is applied to AD treatments
(1) biocompatibility in vitro evaluation
The preparation of various concentrations medicine：It is combined from cerium oxide/iron oxide/nanometer that embodiment 1 is prepared
Material 50mg is dispersed in the aqueous solution of 10ml methylenum careuleum containing 300mg (Tau inhibitors of protein aggregation), after being stirred at room temperature 24 hours
Centrifugation, washing are obtained, and wherein the drugloading rate of methylenum careuleum is 0.36mg/mg.The sterilizing PBS solution of the product different volumes for obtaining
Again dispersion obtains the medicine of various concentrations.
Cerium oxide/the iron oxide of selection people's marrow neuroblastoma cell line (SH-SY5Y) investigation various concentrations/mesoporous
The biocompatibility in vitro of silicon/methylenum careuleum nano composite material.
CCK-8 cytoactives quantitative analysis results are as shown in figure 5, the expression of control groups is only incubated with cell culture fluid
Educate, different pharmaceutical concentration group cell survival rate shows that cerium oxide/iron oxide/mesoporous silicon/methylenum careuleum nanometer is multiple more than 90%
Condensation material has good biocompatibility in vitro.
(2) nerve cell death is suppressed
The preparation of various concentrations medicine：It is combined from cerium oxide/iron oxide/nanometer that embodiment 1 is prepared
Material 50mg is dispersed in the aqueous solution of 10ml methylenum careuleum containing 300mg (Tau inhibitors of protein aggregation), after being stirred at room temperature 24 hours
Centrifugation, washing are obtained, and wherein the drugloading rate of methylenum careuleum is 0.36mg/mg.The sterilizing PBS solution of the product different volumes for obtaining
Again dispersion obtains the medicine of various concentrations.
Cell model is set up：By SH-SY5Y cells in advance and the common incubation 12 of okadaic acid (okadaic acid, OA) is small
When.
Treatment group：The cell of OA pretreatments is given containing the different cerium oxide/iron oxide/mesoporous silicon of concentration/methylenum careuleum nanometer
The cell culture fluid of composite.
Positive controls：The cell of OA pretreatments gives fresh cell medium.
Blank control group：Normal cell gives fresh nutrient solution.
After 24 hours, with the quantitative cytoactives of CCK-8, cerium oxide/iron oxide/mesoporous silicon/methylenum careuleum nano composite material
Suppress the result of the nerve cell death of OA inductions as shown in fig. 6, OA has the obvious effect for promoting nerve cell death thin
Cytoactive is only 24%.Nerve cell death has been after giving cerium oxide/iron oxide/mesoporous silicon/methylenum careuleum nano composite material
Suppress, cytoactive is more than 70%, it was demonstrated that it has the effect of the nerve cell death for suppressing OA inductions.
Embodiment described above has been described in detail to technical scheme and beneficial effect, it should be understood that with
Upper described is only specific embodiment of the invention, be not intended to limit the invention, all to be done in spirit of the invention
Any modification, supplement and equivalent etc., should be included within the scope of the present invention.
Claims (10)
1. a kind of cerium oxide/iron oxide/nanometer composite, it is characterised in that the cerium oxide nano for changing part
The ferric oxide nano crystalline substance of brilliant and part conversion is modified in the surface of amido modified nanometer particle respectively.
2. cerium oxide/iron oxide/nanometer composite according to claim 1, it is characterised in that the part
Conversion refers to carry out part conversion using 2- bromo acids.
3. cerium oxide/iron oxide/nanometer composite according to claim 1, it is characterised in that the part
The particle diameter of the cerium oxide nanocrystal changed is 1~10nm；The particle diameter of the ferric oxide nano crystalline substance that the part is changed is 1~10nm；
The particle diameter of the amido modified nanometer particle is 5~500nm.
4. the preparation method of a kind of cerium oxide/iron oxide/nanometer composite as described in claims 1 to 3 is any,
It is characterised in that it includes following steps：
1) cerous acetate and oleyl amine are added in dimethylbenzene and are reacted, obtain cerium oxide nanocrystal；Carried out using 2- bromo acids
Part is changed, and obtains the cerium oxide nanocrystal of part conversion；
2) iron oleate, oleic acid, oleyl alcohol are added in octadecylene and are reacted, obtain ferric oxide nano brilliant；Entered using 2- bromo acids
Row part is changed, and the ferric oxide nano for obtaining part conversion is brilliant；
3) hexadecyltrimethylammonium chloride and triethanolamine are dissolved in water, 0.5~5h is reacted at 90~100 DEG C, continue to add
Enter tetraethyl orthosilicate and 3- aminopropyl triethoxysilanes react 0.5~5h, obtain amido modified nanometer particle；
4) by part change cerium oxide nanocrystal, part conversion ferric oxide nano it is brilliant and amido modified nanometer grain
Son is added in N-N dimethylformamides, and 3~15h is reacted at 5~60 DEG C, obtains cerium oxide/iron oxide/nanometer
Composite.
5. the preparation method of cerium oxide/iron oxide/nanometer composite according to claim 4, its feature exists
In the step 1) in the mass ratio of cerous acetate and oleyl amine be 1:7~9.
6. the preparation method of cerium oxide/iron oxide/nanometer composite according to claim 4, its feature exists
In the step 2) in iron oleate, oleic acid, oleyl alcohol and octadecylene mass ratio be 1：0.15~0.6：0.5~2：2.5~10.
7. the preparation method of cerium oxide/iron oxide/nanometer composite according to claim 4, its feature exists
In the step 3) in hexadecyltrimethylammonium chloride, triethanolamine, tetraethyl orthosilicate and 3- aminopropyl triethoxysilanes
Rate of charge be：1.5~2.5g：0.03~0.05g：1.4~1.6ml：0.14~0.16ml.
8. the preparation method of cerium oxide/iron oxide/nanometer composite according to claim 4, its feature exists
In the step 4) in part conversion cerium oxide nanocrystal, brilliant and amido modified mesoporous of ferric oxide nano of part conversion
The mass ratio of silicon nano is 1~5：1~5：1~15.
9. a kind of cerium oxide/iron oxide/nanometer composite as described in claims 1 to 3 is any is for preparing
Application in anti-alzheimer medicine.
10. cerium oxide/iron oxide/nanometer composite according to claim 9 is for preparing anti-A Erzi
Application in the silent medicine in sea, it is characterised in that the anti-alzheimer medicine is the medicine with Tau albumen as target spot.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710039529.8A CN106860427B (en) | 2017-01-19 | 2017-01-19 | Cerium oxide/iron oxide/mesoporous silicon nano composite material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710039529.8A CN106860427B (en) | 2017-01-19 | 2017-01-19 | Cerium oxide/iron oxide/mesoporous silicon nano composite material and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106860427A true CN106860427A (en) | 2017-06-20 |
| CN106860427B CN106860427B (en) | 2019-12-17 |
Family
ID=59157988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710039529.8A Active CN106860427B (en) | 2017-01-19 | 2017-01-19 | Cerium oxide/iron oxide/mesoporous silicon nano composite material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106860427B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969757A (en) * | 2018-07-11 | 2018-12-11 | 浙江大学 | Load the cerium oxide nano composite hydrogel and preparation method and application of microRNA |
| CN109771644A (en) * | 2019-03-04 | 2019-05-21 | 浙江大学 | A kind of nanocomposite and preparation method and application |
| CN109806278A (en) * | 2019-02-01 | 2019-05-28 | 浙江大学 | The application of the polyethyleneglycol modified microminiature cerium oxide nanocrystal of phosphatide |
| CN110960695A (en) * | 2019-12-09 | 2020-04-07 | 浙江大学 | Gold/mesoporous silicon/iron oxide nano composite material and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727443A (en) * | 2012-06-29 | 2012-10-17 | 陈士忠 | Clathrate of mesoporous silicon oxide/Fe3O4 magnetic nano-grade complex and ibuprofen |
| EP2537532A1 (en) * | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| CN103536625A (en) * | 2013-09-27 | 2014-01-29 | 安徽师范大学 | Nanometer cerium oxide composite and preparation method thereof as well as antioxidant |
| CN103768620A (en) * | 2014-01-24 | 2014-05-07 | 中国科学院上海硅酸盐研究所 | Fe/mesoporous silica nano composite material and preparation method and application thereof |
-
2017
- 2017-01-19 CN CN201710039529.8A patent/CN106860427B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2537532A1 (en) * | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| CN102727443A (en) * | 2012-06-29 | 2012-10-17 | 陈士忠 | Clathrate of mesoporous silicon oxide/Fe3O4 magnetic nano-grade complex and ibuprofen |
| CN103536625A (en) * | 2013-09-27 | 2014-01-29 | 安徽师范大学 | Nanometer cerium oxide composite and preparation method thereof as well as antioxidant |
| CN103768620A (en) * | 2014-01-24 | 2014-05-07 | 中国科学院上海硅酸盐研究所 | Fe/mesoporous silica nano composite material and preparation method and application thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969757A (en) * | 2018-07-11 | 2018-12-11 | 浙江大学 | Load the cerium oxide nano composite hydrogel and preparation method and application of microRNA |
| CN108969757B (en) * | 2018-07-11 | 2021-07-27 | 浙江大学 | MicroRNA-loaded cerium oxide nano composite hydrogel and preparation method and application thereof |
| CN109806278A (en) * | 2019-02-01 | 2019-05-28 | 浙江大学 | The application of the polyethyleneglycol modified microminiature cerium oxide nanocrystal of phosphatide |
| CN109806278B (en) * | 2019-02-01 | 2021-08-10 | 浙江大学 | Application of phospholipid polyethylene glycol modified subminiature cerium oxide nanocrystal |
| CN109771644A (en) * | 2019-03-04 | 2019-05-21 | 浙江大学 | A kind of nanocomposite and preparation method and application |
| CN110960695A (en) * | 2019-12-09 | 2020-04-07 | 浙江大学 | Gold/mesoporous silicon/iron oxide nano composite material and preparation method and application thereof |
| CN110960695B (en) * | 2019-12-09 | 2021-06-15 | 浙江大学 | Gold/mesoporous silicon/iron oxide nano composite material and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106860427B (en) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106860427A (en) | A kind of cerium oxide/iron oxide/nanometer composite and its preparation method and application | |
| Alphandery et al. | Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy | |
| Ferrari et al. | Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome | |
| Foster et al. | Radiosensitization of anoxic cells by metronidazole | |
| Zhang et al. | Selenium deficiency facilitates inflammation through the regulation of TLR4 and TLR4-related signaling pathways in the mice uterus | |
| CN110743012A (en) | Preparation method and application of glucose oxidase modified mesoporous manganese dioxide pharmaceutical composition | |
| Haggerty et al. | Phenylalanine Hydroxylase in Cultured Hepatocytes: I. HORMONAL CONTROL OF ENZYME LEVELS | |
| CN104758300A (en) | Antibacterial applications of vitamin D and vitamin D composition | |
| CN115089723A (en) | Glutathione and hydrogen peroxide sensitive manganese-based nanoparticles and preparation method and application thereof | |
| CN109498807B (en) | Up-conversion nanoparticle oxygen-independent photodynamic diagnosis and treatment probe and preparation method thereof | |
| Yang et al. | Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma | |
| Cao et al. | A study of preoperative methionine-depleting parenteral nutrition plus chemotherapy in gastric cancer patients | |
| CN106334190B (en) | A kind of multiple response mechanism compound pharmaceutical carrier and preparation method thereof | |
| CN105670998B (en) | A kind of method of calcification cancer cell | |
| CN107281172A (en) | Application of the melbine in the medicine for preparing cervical carcinoma | |
| CN106512029A (en) | Nano-probe with apoptosis target function and preparation and application | |
| Ren et al. | Smart Fe3O4@ ZnO core-shell nanophotosensitizers potential for combined chemo and photodynamic skin cancer therapy controlled by UVA radiation | |
| CN109589334A (en) | A kind of nano enzyme antioxidant and preparation method thereof | |
| CN108721313A (en) | A kind of Vitamin D receptor agonist | |
| CN103145167A (en) | Controllable synthesis of lanthanum hydroxide nano-particles | |
| CN111298139B (en) | Nuclear magnetic imaging guidance-based targeted nano-drug for overcoming drug resistance caused by tumor hypoxia and preparation method and application thereof | |
| CN103524567B (en) | A kind of anti-human osteosarcoma is containing the application of zinc heteropoly compound | |
| CN113117078A (en) | Novel tumor treatment drug AuNCs @ GTTN and preparation method and application thereof | |
| CN103191060B (en) | Amphipathic carboxymethyl glucan-modified magnetic lipidosome, and preparation and application methods thereof | |
| CN107778378A (en) | Mannose-modified chitosan stearic acid grafting and preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |